The addition of a novel genomic classifier (GC) during active surveillance for prostate cancer (PCa) was shown to predict disease progression independently from clinical risk assessment tools such as multiparametric magnetic resonance imaging (mpMRI), according to a recent study presented at the Society of Urologic Oncology (SUO) 25th Annual Meeting. ...
Prostate Cancer Diagnostics
Advertisement
Latest News
Clarity's head-to-head trial evaluates diagnostic performance of 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11.
18F rhPSMA-7.3 (rhPSMA) PET/MRI imaging is a potential "one-stop shop" for detecting biochemically recurrent prostate cancer.
The CLARIFY trial leveraged PSMA PET imaging for personalized prostate cancer treatment and detecting distant metastases.
Advanced PSMA PET imaging improved surgical outcomes for patients with high-risk prostate cancer in the CLARIFY trial.
The COBRA study on SAR-bisPSMA for prostate cancer detection will be presented at the EANM 2024 Congress.
Dr. Pobel offers an overview of the ancillary study of the PEACE-1 trial, including how immunohistochemistry was used.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Advertisement
Section Editor
Geoffrey Johnson, MD, PhDChair of the Radiopharmaceutical Trial Team | Mayo Clinic
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.